Monotherapy of oral hypoglycemics in chronic diabetes rarely maintain the optimum glycemic control and is considered the major cause for late onset complications. In this study combination of rosiglitazone (Rosi-0.2 mg/kg) with metformin (Met- 50 mg/kg) or glimepiride (Gmp – 0.2 mg/kg) orally once daily for 4 weeks was tested against type 2 diabetes mellitus (T2DM) induced by nicotinamide (NA-230 mg/kg, i.p) and streptozotocin (STZ-65 mg/kg, i.p) in male Wistar rats. Results indicated that experimental T2DM significantly (P<0.001) increased micronucleated erythrocytes, sperm shape abnormality and decreased the P/N (polychromatic: normochromatic erythrocytes) ratio, sperm count and weight of testis along with an increase in the oxidative stress and blood glucose level compared to normal animals. Administration of Rosi+Met significantly (P<0.05) reduced the population of micronucleated erythrocytes, sperm shape abnormality, hyperglycemia besides improving the sperm count and antioxidant defense system in the diabetic rats. However, Rosi+Gmp activity was restricted to only the antidiabetic effect. The observations suggest that Rosi+Met reduced the somatic and germinal cell damages in the diabetic animals owing to the antioxidant property.

This content is only available via PDF.
You do not currently have access to this content.